Afternoon Guys. I contacted Tony Keating about RAp's interpretations of the Pneumonia Result.
I will not copy and paste his email as he has not given me explicit permission to post it here, but his response was that the results give the Team confidence in achieving success in the US Study. The NPA for Pneumonia may appear low, but when one considers the difficulty in clinical diagnosis, often providing a diagnosis for more than one illness (for example pneumonia and asthma for example) WHICH IS ACCURATE, BUT IS NOT SHOWN IN THE RESULTS. The most recent test results cannot be compared to the previous results as THEY ARE NOT THE SAME TEST.
Once again, I commend TK and the Team at RAP. They are always transparent, always prepared, and always communicating with their shareholders.
- Forums
- ASX - By Stock
- RAP
- Ann: ResApp Provides Updated Australian Paediatric Study Results
Ann: ResApp Provides Updated Australian Paediatric Study Results, page-85
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
-
- There are more pages in this discussion • 204 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review